<DOC>
	<DOC>NCT01419236</DOC>
	<brief_summary>The purpose of this study is to see if testosterone solution 2% can impact symptoms of ejaculatory dysfunction in men with low testosterone.</brief_summary>
	<brief_title>A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Total testosterone level &lt;10.4 nanomoles per liter (nmol/L) [300 nanograms per deciliter (ng/dL)] at screening Presents with 1 or more of the following symptom(s) of ejaculatory dysfunction: delayed ejaculation, anejaculation, decreased force of ejaculation, or decreased ejaculatory volume, as determined by investigator assessment ProstateSpecific Antigen (PSA) &lt;4 nanograms per milliliter (ng/mL) at screening Sexual partner who is or becomes pregnant at any time during the study Premature ejaculation as determined by investigator assessment Currently receiving testosterone replacement therapy or have a history of insufficient response to testosterone replacement therapy for ejaculatory dysfunction symptoms Currently receiving treatment with cancer chemotherapy or antiandrogens History of use of estrogenizing agents Current use of warfarin History of selective serotonin reuptake inhibitor (SSRI) and/or serotoninnorepinephrine reuptake inhibitor (SNRI) treatment in the 6 months prior to screening History of frequent opioid use within 30 days prior to screening, with exception of treatment for chronic pain as determined by investigator. Body Mass Index (BMI) &gt;35 kilograms per square meter (kg/m^2) at screening Significant peripheral neuropathy affecting erectile, ejaculatory, or orgasmic function Hematocrit â‰¥50% at screening Exhibit systolic blood pressure &gt;170 millimeters of mercury (mm Hg) or &lt;90 mm Hg or diastolic blood pressure &gt;100 mm Hg or &lt;50 mm Hg at screening (if stress is suspected, retest under basal conditions at screening), or have history of malignant hypertension History of any of the following coronary conditions within 90 days of screening: myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention (for example, angioplasty or stent placement) Known or suspected carcinoma (or history of carcinoma) of the prostate or suspicious nodules on digital rectal exam at screening Known or suspected breast cancer (or history of breast cancer) or other active cancer (with the exception of nonmelanotic skin cancer)</criteria>
	<gender>Male</gender>
	<minimum_age>26 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Ejaculatory Dysfunction</keyword>
	<keyword>Orgasmic Dysfunction</keyword>
	<keyword>Sexual Dysfunction</keyword>
	<keyword>Climax Dysfunction</keyword>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Impotence</keyword>
	<keyword>Hypogonadism</keyword>
	<keyword>Low testosterone</keyword>
	<keyword>Low t</keyword>
</DOC>